The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials
A partir d'une revue systématique de la littérature publiée jusqu'en octobre 2023 (6 essais randomisés, 1 368 patientes), cette méta-analyse évalue l'intérêt d'une chirurgie locorégionale chez les patientes atteintes d'un cancer du sein de novo de stade IV
Résumé en anglais
Background: We performed an updated meta-analysis to explore the value of locoregional surgery in de novo stage IV breast cancer patients.
Methods: A literature search was conducted to identify randomized controlled trials comparing primary tumor resection with systemic therapy in de novo stage IV breast cancer. The hazard ratio (HR) of overall survival (OS), local relapse-free survival (LRFS), and distant relapse-free survival (DRFS) were estimated and pooled.
Results: Six studies were eligible, including a total of 1368 patients. Both OS (HR = 0.86; 95 %CI: 0.77–0.96; p = 0.01; I2 = 45 %) and LRFS (HR = 0.35; 95 %CI: 0.20–0.62; p = 0.0003; I2 = 83 %) were significantly improved with locoregional surgery compared with systemic therapy alone. There was no significant difference in terms of DRFS (HR = 0.96; 95 %CI: 0.41–2.22; p = 0.92; I2 = 86 %). The OS benefit was more pronounced in hormone receptor-positive patients (HR = 0.79; p = 0.003) and HER2-negative patients (HR = 0.80; p = 0.003).
Conclusions: This study demonstrated that locoregional surgery conferred significant OS and LRFS benefits in de novo stage IV breast cancer patients and may serve as an alternative choice for selected patients.
